Abstract |
A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam. We now report the results of a three-site, 6-week, double-blind, fixed-dose study comparing alprazolam 2 mg, alprazolam 6 mg, and placebo in 94 patients with panic disorder with or without agoraphobia. Both alprazolam treatment groups (6 mg and 2 mg) improved significantly more than did the placebo treatment group on most outcome measures. Only a few statistically significant differences between the 6 mg and 2 mg alprazolam groups were discerned, although the pattern of treatment response across measures suggested a dose effect. Dropouts in the placebo group were primarily due to lack of efficacy and in the alprazolam 6 mg group were due to side effects, which may have contributed to the limited differences between groups at study end. The findings suggest that many patients may require less than 6 mg of alprazolam per day for effective treatment of panic disorder.
|
Authors | R B Lydiard, I M Lesser, J C Ballenger, R T Rubin, M Laraia, R DuPont |
Journal | Journal of clinical psychopharmacology
(J Clin Psychopharmacol)
Vol. 12
Issue 2
Pg. 96-103
(Apr 1992)
ISSN: 0271-0749 [Print] United States |
PMID | 1573046
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Agoraphobia
(blood, drug therapy, psychology)
- Alprazolam
(administration & dosage, adverse effects, pharmacokinetics)
- Arousal
(drug effects)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Neurologic Examination
- Panic Disorder
(blood, drug therapy, psychology)
- Personality Assessment
|